Improvements in left ventricular ejection fraction and quality of life in patients with heart failure who undergo coronary artery bypass surgery

2016 ◽  
Vol 222 ◽  
pp. 671-673 ◽  
Author(s):  
Sean Lal ◽  
Lisa Turner ◽  
Catherine Powell ◽  
Michael Wilson ◽  
Paul Bannon
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Coronary Artery Bypass Surgery ◽  
Bypass Surgery ◽  
Artery Bypass ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction ◽  
Patients With Heart Failure

scholarly journals Quality of Life for Saudi Patients With Heart Failure: A Cross-Sectional Correlational Study

2015 ◽  
Vol 8 (3) ◽  
pp. 49 ◽  
Author(s):  
Mohannad Eid AbuRuz ◽  
Fawwaz Alaloul ◽  
Ahmed Saifan ◽  
Rami Masa'deh ◽  
Said Abusalem
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Saudi Arabia ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Cross Sectional ◽  
Ventricular Ejection Fraction ◽  
Patients With Heart Failure ◽  
Saudi Patients

<p><strong>INTRODUCTION:</strong> Heart failure is a major public health issue and a growing concern in developing countries, including Saudi Arabia. Most related research was conducted in Western cultures and may have limited applicability for individuals in Saudi Arabia. Thus, this study assesses the quality of life of Saudi patients with heart failure.</p> <p><strong>MATERIALS &amp; METHODS:</strong><em> </em>A cross-sectional correlational design was used on a convenient sample of 103 patients with heart failure. Data were collected using the Short Form-36 and the Medical Outcomes Study-Social Support Survey.</p> <p><strong>RESULTS:</strong> Overall, the patients’ scores were low for all domains of Quality of Life. The Physical Component Summary and Mental Component Summary mean scores and SDs were (36.7±12.4, 48.8±6.5) respectively, indicating poor Quality of Life. Left ventricular ejection fraction was the strongest predictor of both physical and mental summaries.</p> <p><strong>CONCLUSION:</strong> Identifying factors that impact quality of life for Saudi heart failure patients is important in identifying and meeting their physical and psychosocial needs.</p>

scholarly journals Optimism and quality of life in patients with heart failure

2017 ◽  
Vol 16 (6) ◽  
pp. 725-731 ◽  
Author(s):  
I.H. Kraai ◽  
K.M. Vermeulen ◽  
H.L. Hillege ◽  
T. Jaarsma ◽  
T. Hoekstra
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Dispositional Optimism ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Physical Factors ◽  
Ventricular Ejection Fraction ◽  
Life Orientation Test ◽  
Patients With Heart Failure

AbstractObjectivesHealth-related quality of life (HR-QoL) of patients with heart failure (HF) is low despite the aim of HF treatment to improve HR-QoL. To date, most studies have focused on medical and physical factors in relation to HR-QoL, few data are available on the role of emotional factors such as dispositional optimism. This study examines the prevalence of optimism and pessimism in HF patients and investigates how optimism and pessimism are associated with different patient characteristics and HR-QoL.MethodsDispositional optimism was assessed in 86 HF patients (mean age 70 ± 9 years, 28% female, mean left ventricular ejection fraction 33%) with the Revised Life Orientation Test (LOT-R). HR-QoL was assessed with the Minnesota Living with Heart Failure Questionnaire and the EuroQol.ResultsThe (mean ± SD) total score on the LOT-R was 14.6 ± 2.9 (theoretical range 0–24) and the scores on the subscales optimism and pessimism were 8.1 ± 1.9 and 5.5 ± 2.5, respectively. Higher age was related to more optimism (r = 0.22, p < 0.05), and optimism was associated with higher generic HR-QoL (B = 0.04, p < 0.05).Significance of resultsThe association found between optimism and generic HR-QoL of HF patients can lead to promising strategies to improve HF patients’ HR-QoL, particularly because the literature has indicated that optimism is a modifiable condition.

scholarly journals Expert consensus regarding treatment of iron deficiency in stable and decompensated patients with heart failure

Kardiologiia ◽  
2021 ◽  
Vol 61 (4) ◽  
pp. 73-78
Author(s):  
Yu. V. Mareev ◽  
S. R. Gilarevsky ◽  
Yu. L. Begrambekova ◽  
Yu. M. Lopatin ◽  
A. A. Garganeeva ◽  
...  
Keyword(s):  
Heart Failure ◽  
Iron Deficiency ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Ferric Carboxymaltose ◽  
Ventricular Ejection Fraction ◽  
Patients With Heart Failure ◽  
High Prevalence ◽  
Acute Decompensation

In recent years there has been significant interest in treating iron deficiency (ID) in patients with heart failure (HF) due to its high prevalence and detrimental effects in this population. As stated in the 2020 Russain HF guidelines, Intravenous ferric carboxymaltose remains the only proven therapy for ID.This document was prompted by the results from the recent AFFIRM-AHF trial which demonstrates that treatment of ID after acute HF decompensation reduces the risk of future decompensations. Experts have concluded that in HF patients with acute decompensation, a left ventricular ejection fraction of < 50% and ID, Intravenous ferric carboxymaltose reduces future HF hospitalisations. Patients with stable HF may also benefit from treatment of ID to improve quality of life and alleviate symptoms.  It is, therefore, reasonable to screen for and treat ID in patients with HF.

Pharmacological Management of a Heart Failure Patient with Severe Obesity

Cardiology ◽  
2017 ◽  
Vol 138 (Suppl. 1) ◽  
pp. 11-12 ◽  
Author(s):  
Gerardo Riccio
Keyword(s):  
Heart Failure ◽  
Severe Obesity ◽  
Heart Function ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Pharmacological Management ◽  
Ventricular Ejection Fraction ◽  
Present Case Report ◽  
Patients With Heart Failure

Obesity is one of the commonest comorbidities in patients with heart failure, and it is associated with increased mortality risk. However, obese patients are often underrepresented in clinical trials and therefore evidence on their management remains scant. In order to expand knowledge on the management of these patients, anecdotal reports may be considered. In the present case report, we discuss the successful management of an obese patient who received sacubitril/valsartan therapy. This treatment was initiated after a 12-month period of losartan therapy, which did not provide any benefit in terms of heart function. Importantly, during this period the patient required frequent hospitalizations, with a marked decrease in quality of life. After the switch to sacubitril/valsartan, a 10% increase in left ventricular ejection fraction was observed (from 30 to 40%) over a 12-month period. Moreover, no hospitalizations were required, and the patient was able to carry on at least some of his daily activities.

Abstract 3040: Coronary Artery Bypass Surgery In 14,956 Patients With Cardiogenic Shock: The Society Of Thoracic Surgeons National Database Experience

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Rajendra H Mehta ◽  
Joshua D Grab ◽  
Sean M O’Brien ◽  
Donald D Glower ◽  
Jeffrey P Jacobs ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Cardiogenic Shock ◽  
Coronary Artery Bypass ◽  
Coronary Artery Bypass Surgery ◽  
Bypass Surgery ◽  
Artery Bypass ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
National Database ◽  
Ventricular Ejection Fraction

Background . While only a small minority of patients undergo coronary artery bypass surgery (CABG) in the setting of cardiogenic shock (CS), these patients face a high risk for mortality and morbidity. There exist few studies that characterize clinical features and outcomes in CS patients undergoing CABG in contemporary community practice. Methods . We evaluated data of 14,956 patients with CS in comparison with 693637 without CS undergoing CABG between 2002 and 2005 at hospitals participating in the Society of Thoracic Surgeons National Database. Clinical, angiographic and operative features and in-hospital outcomes were studied in patients with and without CS. Results . Patients with preoperative CS constituted 2.1% of patients undergoing CABG yet accounted for 16% of all CABG deaths. These patients had greater comorbid conditions and left main disease and lower left ventricular ejection fraction. In-hospital events and length of hospital stay (median 96 vs. 36 days) were significantly higher in CS patients. Operative mortality was high (rising from 20% for isolated CABG, to 33% for CABG+ valve surgery, to 58% for CABG+ ventricular septal repair). While mortality for CABG surgery overall has declined significantly overtime (p for trend< .0001), mortality for CS patients have not changed significantly over the 4 year study period (p= .07, Figure ). Conclusions . Patients with CS represents minority of patients undergoing CABG, yet with persistently high operative risks. These patients in fact account for 1 of every 7 deaths in patients undergoing CABG. Ongoing efforts are warranted to continuously develop and evaluate new strategies to improve outcomes of these patients.

Sign in / Sign up

Export Citation Format

Share Document